Madrigal Pharmaceuticals, Inc. (MDGL) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
High 527.86 at 1:15 pm ET, low 520.59 at 10:00 am ET.
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
the bull case· 3
413
managers reporting a position in thirteen F filings
13fJun 30 '2633
managers whose positions make up four fifths of reported value
13fJun 30 '261.06%
State Street SPDR S and P Biotech ETF largest fund weight on file
n-portJun 30 '26the bear case· 3
39.00%
revenue reliance on the largest disclosed customer Customer A
10-Kfiled Feb 26 '259 of 22
largest reporting managers that cut their stake in the latest quarter
13fJun 30 '26−1.58%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 4 '26 report. Not a forecast, not advice.
Of the 6 companies Madrigal Pharmaceuticals, Inc. moves with most closely, none share its SEC classification.
Measured against 500 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
tall tick = annual report · 2 on record
Madrigal Pharmaceuticals, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
MDGL (Madrigal Pharmaceuticals, Inc.) has 9 disclosed suppliers and 6 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
415 managers report a position worth $13.3B between them, and 33 of them hold 80% of it.